AndhraNews.net
Home » Business News » 2014 » December » December 31, 2014

Plandai Biotechnology, Inc. Provides Year-End Shareholder Update


December 31, 2014 - Logan, UT

LOGAN, UT--(Marketwired - December 31, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today provided an update to shareholders that reviews the company's accomplishments over the preceding twelve months.

Roger Duffield, Chief Executive Officer of Plandaí, stated, "The past twelve months have seen Plandaí achieve several key milestones.  After recently completing the Senteeko production facility and processing the first batches of Phytofare®, we felt shareholders would appreciate an overview of our achievements in 2014."

First, in late 2013, Plandaí entered into the cannabis research arena, but it was this year that the Company solidified its position in the industry by securing a licensing agreement with Diego Pellicer and then obtaining a consent letter from the Minster of Health in Uruguay to commence growing cannabis and producing an extract for animal testing.  This consent allows Plandaí to legally conduct the research necessary to ascertain the medicinal benefits of the complete cannabinoid profile containing the non-psychoactive THC-A, THC-B and CBD acids.

Mr. Duffield said of Plandaí's move into the cannabis research arena, "We believe that our proprietary processing system will allow us to extract various chemicals in cannabis in their natural, non-psychoactive forms, which could prove hugely beneficial to pharmaceutical research. Our plan at this point is to establish the cannabis growing infrastructure in Uruguay which will allow us to better control the chemical profile and then conduct our research to determine the possible efficacy of cannabis in treating various medical conditions."

Second, following years of supporting research and projections of improved bioavailability, in September 2014 Plandaí released the long-awaited clinical data showing that its Phytofare Catechin Complex demonstrated ten times greater bioavailability over a generic catechin extract.  This human study, which involved 26 test subjects who underwent multiple blood draws over a 24-hour period, showed that all eight active catechins from the green tea plant made it into the bloodstream and remained there for 24 hours, compared to the generic tea extract where only two catechins were found in the blood and remained there only six hours. 

Commenting on the study Mr. Duffield said, "Previous studies involving lycopene, phytoene and phytofluene had been conducted and published by Dr. Betty Ishida, a research biologist with the USDA, which showed increased bioavailability from our proprietary extraction method; however, this new catechin study represented scientific validation in human subjects and quantified that increase in a tangible, measurable way." 

Third, Plandaí completed the commissioning of its Senteeko extraction facility in South Africa.  This project encompassed over two years and $13 million.  Mr. Duffield said, "We now have the potential to process up to ten tons of live-plant material every day, yielding approximately four tons of finished Phytofare® every month.  Our productions should then double once additional tea comes online in late 2015.  The factory has commenced producing Phyofare® green tea Catechin Complex and we are now having the final chemical profile validated by an independent laboratory before commencing shipment of samples to potential customers."

Finally, in 2014 Plandaí moved forward with its goals of securing its intellectual property base, and was granted two trademarks in South Africa for its tradename "Phytofare" and has three pending trademark applications in the United States.

Mr. Duffield concluded, "We also met several other smaller milestones including the completion of a topical anti-aging study in humans which showed favourable results and we started cultivating several new plants in our nursery for future research. We had some major renovations completed on the Senteeko property including significant renovations to the roads and bridges in addition to repairing the dam wall which had been damaged prior to our taking over the property."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.  Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.  Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical.  For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Contact:
Andrew Beyer
Phone: 888-627-6902
Email:  investor@Plandaíbiotech.com

MarketWire

Comment on this story

Share